September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
Children with Lupus and Diabetes Are Likely to Also Have Depression
Children with systemic lupus erythematosus (SLE)/mixed connective tissue disease (MCTD) often suffer from significant bouts of depression and potentially suicide ideation, a study in the Journal of Pediatrics determined.
Growing Evidence that Insulin Plays a Role in Etiology and Severity of Acne Vulgaris
A study in Postᶒpy adds to the growing evidence of a link between insulin and carbohydrate metabolism in the etiology and severity of acne vulgaris. While the clinical evidence on this connection is still disputed, the majority of recent studies has pointed to a significant connection between the condition and insulin levels.
FDA Warning: Disabling Joint Pain Seen in Diabetes Drugs
The US Food and Drug administration today issued a warning that the type 2 diabetes medicines sitagliptin (Januvia/Merck) linagliptin (Tradjenta/BI), and alogliptin (Nesina/Takeda) "may cause joint pain that can be severe and disabling."
New Glycemic Control Combo Approved for Type 2 Diabetes
The US Food and Drug Administration approved a new glycemic control treatment for type 2 diabetes for adults, a combination product made of empagliflozin (Jardiance/ Boehringer Ingelheim) and metformin hydrochloride. It will be marketed as Synjardy in a joint venture with Eli Lilly.